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EDITORIAL
The year in review: progress in brain barriers 
and brain fluid research in 2018
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Abstract 
This editorial focuses on the progress made in brain barrier and brain fluid research in 2018. It highlights some recent 
advances in knowledge and techniques, as well as prevalent themes and controversies. Areas covered include: mod‑
eling, the brain endothelium, the neurovascular unit, the blood–CSF barrier and CSF, drug delivery, fluid movement 
within the brain, the impact of disease states, and heterogeneity.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Editorial
There continues to be much interest in brain barrier and 
brain fluid research. Many important papers (too many 
to be cited here) have been published in the field in 2018. 
The purpose of this editorial is to highlight some recent 
advances and themes for the readership of Fluids and 
Barriers of the CNS. As always, the selection of papers 
discussed is idiosyncratic and the discussions are neces-
sarily brief. The journal welcomes more in-depth reviews 
as well as novel research articles in any of the areas 
discussed.
Modeling
In vitro blood–brain barrier (BBB)/neurovascular unit (NVU) 
modeling
Engineering the BBB/NVU in vitro is challenging: models 
differ in complexity and their ability to replicate different 
in vivo parameters. The utility of such models varies with 
the specific questions being addressed. However, there 
is a question as to what basic parameters such models 
should exhibit. DeStefano et  al. have recently proposed 
a series of benchmarks for in vitro BBB models [1] that 
might form a basis for such decisions or lead to a discus-
sion of validation parameters.
One of the recent advances in BBB modeling is the 
use of human-induced pluripotent stem cells (iPSCs) 
to derive different cells of the neurovascular unit (e.g. 
endothelial cells, pericytes, astrocytes). Such models are 
now being pursued by multiple groups (e.g. [2–7]). The 
use of human iPSCs may aid in the translation of basic 
science to the clinic. In addition, it is possible to gener-
ate such models from patient-derived iPSCs allowing 
examination of the impact of patient-specific mutations 
[8]. Thus, Lee et al. [5] found that brain endothelial cells 
derived from iPSCs from patients with childhood cer-
ebral adrenoleukodystrophy have impaired barrier prop-
erties and accumulate lipid droplets, effects that were 
rescued by treatment with a block copolymer.
While there are many studies that have examined 
the role of different cell types (particularly endothelial 
cells, astrocytes and pericytes) on the characteristics of 
in  vitro NVU/BBB models, the importance of extracel-
lular matrix has generally received less attention. Katt 
et  al. [4] and Al-Ahmad et  al. [2] recently showed the 
importance of different extracellular matrix molecules on 
iPSC-derived BBB models. BBB modeling is a fast devel-
oping field (reviewed in [9]). One of the goals of multiple 
groups is the development of a ‘barrier-on-a-chip’. Such 
chips may be very useful for drug testing and alternative 
designs are reported [10–12].
Computer modeling
As well in vitro modeling, there have been a number of 
important studies using computer (in silico) modeling 
in 2018, particularly in relation to the movement of fluid 
through the proposed glymphatic system. Thus, Faghih 
et al. [13] and Rey and Sarntinoranont [14] modeled fluid 
movement within the perivascular space. Their findings 
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throw skepticism on the importance of perivascular bulk 
fluid flow, an essential component of the glymphatic sys-
tem. Another example of in silico modeling are efforts to 
predict brain:blood unbound concentration ratios for dif-
ferent drugs and, thus, reduce the expense of developing 
brain therapies [15, 16].
Animal modeling
The use of non-mammalian models to examine the 
blood–brain, blood–retinal and blood–CSF barriers con-
tinues to gain interest [17]. The relative ease and lower 
cost of genetic manipulation and brain visualization has 
spurred the use of zebrafish for barrier studies [18, 19], 
while others have started examining relevant barriers in 
drosophila (fruit flies). Thus, Zhang et al. [20] examined 
the perineural glia of drosophila that form the insect 
equivalent of a ‘blood’-brain barrier and showed a circa-
dian rhythm in barrier function.
Brain endothelium
Brain endothelial junctions: importance, structure 
and regulation
Brain endothelial tight junctions (TJs) are an essential 
component of the NVU/BBB, helping protect the brain 
from potentially harmful blood-borne compounds. TJ 
disruption can contribute to brain injury in a number of 
types of brain injury or disease. In 2017, Menard et  al. 
[21] found that social stress in mice, a model of depres-
sion, reduced expression of claudin-5, that reducing 
claudin-5 experimentally could induce depression-like 
symptoms and that treatment with a known anti-depres-
sant increased claudin-5 expression. These results sug-
gest an important impact of changes in the NVU/BBB 
on brain function and animal behavior. Cheng et  al. 
[22] recently examined a prolonged learned ‘helpless-
ness’ model of depression in rats and found that BBB 
disruption contributed to an inability to recover from 
the imposed stress. Another study examining the basis 
of psychiatric disease (schizophrenia) suggests a link 
between neural cell and cerebrovascular development 
[23]. Furthermore, Todd et al. [24] recently used focused 
ultrasound to locally ‘open’ the BBB in rats and found this 
treatment disrupted both local and inter-hemispheric 
functional connectivity within the brain, again indicating 
an important role of NVU/BBB integrity in overall brain 
function. While adoption of focused ultrasound is pro-
gressing for enhancing brain drug delivery, safety con-
cerns for this technology also need to be addressed [25, 
26], including subtle behavioral effects. Overall, the link 
between the cerebrovasculature and behavior is greatly 
understudied.
There have been a number of important studies in 2018 
on the regulation of brain endothelial TJs in health and 
disease with some focusing on cell signaling pathways. 
For example, Isawa et al. [27] showed the importance of 
β1-integrin and extracellular matrix interactions in reg-
ulating endothelial tight junctions. Other recent studies 
documented the importance of lysophosphatidic acid, 
Wnt, PI3K/Akt and tumor necrosis factor-α signaling 
in regulating brain endothelial TJs [28, 29]. Wang et  al. 
[30] identified microRNA-130a as an important regula-
tor of BBB function in cerebral ischemia and observed 
that this microRNA downregulates occludin expression 
by inhibiting Homebox A5 expression. That study is one 
of several demonstrating the importance of microRNAs 
in up- or down-regulating brain endothelial permeability 
(e.g. microRNA-143, -146a, -149-5p, -21, -96 and -155 
[31–36]). Interestingly, in addition, Ma et  al. [37] found 
that claudin-5 affects the expression of long non-coding 
RNAs (lncRNAs) in brain endothelial cells thereby regu-
lating BBB properties in brain metastases.
Most current work on brain endothelial TJ regulation 
employs animals or animal-derived cells. There is a con-
cern that species differences, e.g. in humans, in regula-
tion may exist. Wang et  al. [38] examined the potential 
role of one protein, periaxin, present in brain endothelial 
cells in humans but not in multiple other species. They 
found that periaxin strengthens barrier permeability and 
attenuates the expression of inflammatory mediators.
In terms of brain endothelial junction proteins, most 
attention has traditionally focused on the role of TJ pro-
teins, although the importance of adherens junction 
proteins in barrier formation and function is recognized 
[39]. A recent study highlights the importance of brain 
endothelial gap junctions, and particularly connexin-43, 
in the barrier changes that occur in cerebral cavernous 
malformations type III by remodeling the TJs [40].
There is much interest in developing methods to reduce 
or increase TJ protein expression in brain endothelial 
cells to either enhance drug delivery or improve barrier 
function (e.g. in disease). One approach has been the use 
of claudin-targeted peptides that induce claudin internal-
ization/degradation. Sladojevic et  al. [41] reported that 
cerebral ischemia induces the novel expression of clau-
din-1 in the cerebral endothelium and that reducing its 
expression, with a claudin-1 targeted peptide, improves 
endothelial barrier permeability long-term.
Brain endothelial transcellular transport
Brain endothelial cells possess a wide range of trans-
porters that are important in facilitating the entry of 
compounds into brain (such as the glucose transporter, 
GLUT1) or preventing their entry (such as multidrug 
resistance protein 1, P-glycoprotein). One difficulty in 
assessing the importance of different transporters in 
nutrient or xenobiotic deposition is that they often have 
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overlapping substrate specificities and the use of quan-
titative proteomics to assess transporter expression 
continues to grow. An example is a recent study by Al-
Feteisi et al. [42] who reported on rat brain microvessel 
transporters. This approach can also be used to compare 
transporter expression across different barrier tissues, 
such as the arachnoid-epithelial cell barrier [43].
The relative importance of BBB-mediated efflux of 
different compounds from brain parenchyma versus 
alternative egress routes (particularly the perivascular 
pathway) is the subject of a major review by Hladky and 
Barrand [44]. This is a very important and controversial 
topic impacting normal brain function, multiple disease 
states (e.g. β-amyloid clearance in Alzheimer’s disease) 
and drug delivery.
Because brain to blood efflux (e.g. via ATP-biding cas-
sette (ABC) transporters) has an important role in reg-
ulating both the brain concentrations of endogenous 
compounds and xenobiotics, there is great interest in 
how such transport is regulated. Recent examples include 
reports by Hartz et  al. [45], who found that preventing 
P-glycoprotein ubiquitination could be used to decrease 
β-amyloid levels in a mouse model of Alzheimer’s dis-
ease; Xie et  al. [46] who provide evidence that micro-
RNA-298 regulates P-glycoprotein; and Shin et  al. [47] 
who showed that estrogen represses breast cancer resist-
ance protein expression and activity in brain endothelial 
cells after ischemia. One neglected aspect of blood–brain 
transport studies is whether there may be sex differences. 
Brzica et al. [48] recently found that there are differences 
in adult male and female rats in the expression and activ-
ity of organic anion transporting polypeptide 1a4 in rat 
brain microvessels. Whether similar differences exist in 
humans is an important question because of the implica-
tions for drug delivery.
Another transcellular route across the cerebral 
endothelium is vesicular trafficking. This is particularly 
important for proteins, including potentially therapeutic 
antibodies. A better understanding of trafficking mecha-
nisms and vesicle fate (e.g. transcytosis vs lysosomal deg-
radation) will aid in such therapeutic studies. Haqqani 
et  al. [49] recently delineated antibody trafficking 
between different endosomal compartments. Such mech-
anisms may differ between species and Ribecco-Lutkie-
wicz et al. [6] recently found that a human iPSC-derived 
BBB model can be used to study receptor-mediated tran-
scytosis triggered by antibodies. An important question 
is how brain endothelial transcytosis may be impacted 
by particular disease states? Sadeghian et al. [50] recently 
found that cortical spreading depolarizations triggered 
caveolin-1 dependent endothelial transcytosis.
One important aspect of blood–brain transcellular 
transport mechanisms is that they may be ‘hijacked’ by 
certain viruses allowing brain penetration. The recent 
Brazilian Zika virus outbreak caused microcephaly and 
other neurological conditions. Alimonti et al. [3] used an 
in vitro BBB model derived from human iPSCs to exam-
ine mechanisms of virus transport. They found evidence 
for transcellular penetration involving a receptor tyrosine 
kinase, AXL, suggesting potential targets for therapeutic 
interventions.
Neurovascular unit
Neurovascular signaling
The cells of the NVU (including, endothelial cells, astro-
cytes, pericytes neurons and perivascular macrophages) 
play an important role in regulating cerebrovascular 
function, including permeability [51]. Most attention 
has focused on the role of secreted peptides/proteins 
(e.g. [52]) and, more recently, lipids such as sphingolip-
ids [53], by astrocytes and pericytes in such regulation. 
However, the importance of other signaling mechanisms 
is becoming clear. This includes a role of extracellular 
vesicles/exosomes (reviewed in [54]) and microRNAs 
(see above). Extracellular vesicles are released by a wide 
range of cell types and can contain a variety of signaling 
molecules including proteins, microRNAs and mRNAs. 
Another intriguing possible signaling mechanism has 
been suggested by Errede et al. [55] who described per-
icyte-derived tunneling nanotubes that may be involved 
in pericyte to endothelial cell signaling during normal 
and pathological angiogenesis.
While much attention has focused on the impact of 
pericyte-, astrocyte- and neuronal-derived signals on the 
brain endothelium, there are also important endothelial-
derived signals that affect parenchymal cells. An exam-
ple of such pathways was recently described by Segarra 
et  al. [56] who found that endothelial disabled1 (Dab1) 
is an important regulator within the NVU. Deletion 
of endothelial Dab1 reduces laminin-α4 secretion and 
thereby decreases integrin-β1 signaling in astrocytes 
that, in turn, regulates both neuronal migration and BBB 
function.
Endothelial glycocalyx and the vascular basement 
membrane
Two components of the NVU that receive relatively lit-
tle attention are the endothelial glycocalyx and the vas-
cular basement membrane. Kutuzov et al. [57] examined 
the penetration of different sized tracers into brain and 
found that the glycocalyx on the luminal membrane of 
the cerebral endothelium is a significant barrier to the 
penetration of large molecular weight dextrans. There is 
also recent evidence that preserving the glycocalyx after 
cardiac arrest in rats helps preserve barrier function and 
reduce brain edema formation [58].
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As noted above, in vitro evidence indicates the impor-
tance of extracellular matrix components in determining 
vascular wall properties [4]. The neurovascular base-
ment membrane is secreted by multiple cell types (e.g. 
endothelial cells, pericytes and astrocytes). The molecu-
lar complexity of the vascular basement membrane and 
its structural compartments within the vascular bed are 
now delineated by Hannocks et  al. [59] using cellular 
and molecular markers. This group of investigators pro-
pose that the capillary endothelial cell- and perivascular 
cell-derived proteins are physically separated, potentially 
providing a route for perivascular fluid flow [59, 60] (see 
below).
The blood‑CSF barrier and CSF
Choroid plexus and CSF
The role of the choroid plexus in neuroinflammation 
continues to garner interest, including mechanisms for 
combatting infection [61, 62]. Interestingly, the choroid 
plexus produces high levels of the ‘anti-aging’ protein 
klotho and recent evidence indicates that klotho has a 
major role in regulating the brain/immune interface at 
the choroid plexus [63]. Other results have shown that 
the choroid plexus forms an important niche for T cell 
activation within the brain [64].
Progress continues to be made on identifying ion trans-
porters at the choroid plexus and determining their role 
in regulating fluid movement and CSF composition [65–
67]. For example, Preston et  al. [68] examined the role 
of the transient receptor potential vanilloid 4 (TRPV4) 
cation channel at the choroid plexus epithelium and 
report that activating this channel caused an immediate 
increase in transepithelial ion flux. Modulating this chan-
nel may be a novel way of controlling choroid plexus ion 
transport and, potentially, CSF secretion. Another nota-
ble finding is that a significant portion of CSF produc-
tion may result from molecular transfer of water via the 
action of a Na/K/2Cl cotransporter (NKCC1) expressed 
on the CSF-facing membrane of the choroid plexus [69]. 
This novel mechanism, in concert with aquaporins, may 
be responsible for nearly half of the water flux during 
CSF production.
Several neurological conditions result in changes in 
CSF composition and, therefore, CSF is widely used in 
disease biomarker studies. For example, the use of CSF 
biomarkers in Alzheimer’s disease, cerebral amyloid 
angiopathy and other neurodegenerative diseases, is 
emerging, although there are still areas of technical and 
conceptual controversy (see reviews in [70–73]). While 
the use of blood-borne biomarkers may have major 
advantages, there are still hurdles to overcome for that 
approach [74].
Changes in choroid plexus function with disease may 
contribute to changes in CSF composition. Stopa et  al. 
[75] examined changes in the choroid plexus transcrip-
tome in patients with neurodegenerative disorders 
(Alzheimer’s disease, frontotemporal dementia and 
Huntington’s disease) and found both common and dis-
ease-specific changes. These might be involved in brain 
damage but also brain protection and repair.
While most focus has been on CSF proteins as bio-
markers, there are starting to be growing numbers of 
studies examining RNA and DNA in CSF. For example, 
Dos Santos et al. found evidence that a panel of microR-
NAs in CSF could be used to detect early Parkinson’s dis-
ease [76]. There has also been interest in using CSF DNA 
to examine the presence of mutations or transcript copy 
number variations associated with brain tumors [77].
Arachnoid membrane
Compared to the NVU/BBB and the blood-CSF bar-
rier at the choroid plexus, the blood-CSF barrier at the 
arachnoid membrane has received very little attention. 
Zhang et  al. [43] recently used quantitative proteomics 
to compare transporter expression in the leptomenin-
ges vs. choroid plexus in rat. While some transporters 
were enriched in choroid plexus, others were much more 
highly expressed in the leptomeninges including mul-
tidrug resistance protein 1 (p-glycoprotein), breast 
cancer resistance protein (bcrp) and organic anion 
transporter-1. The role of the arachnoid membrane in 
brain homeostasis and drug disposition deserves greater 
attention.
One potential reason for the high expression of trans-
porters in the leptomeninges is suggested by the recent 
finding that the leptomeninges are the primary source of 
prostaglandin D2, which is involved in sleep regulation 
[78]. This adds to a growing literature indicating that the 
leptomeninges are a source of neuroactive/neurotropic 
factors. Transporter expression at the leptomeninges may 
be involved in regulating the concentration and distribu-
tion of such factors.
Drug delivery
With the rising capabilities of immunotherapy, there 
is great interest in the delivery of therapeutic antibod-
ies to the brain for a variety of neurological conditions, 
including Alzheimer’s disease and advances are being 
made in the design of antibodies to enhance CNS deliv-
ery (reviewed by Stanimirovic et al. [79]). Most preclin-
ical work on antibody delivery is performed in rodents 
and differences between species are a concern for 
translational applications. Wang et  al. [80] examined 
whether the CSF/serum ratio after systemic antibody 
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delivery differs between rats and cynomolgus monkeys 
and found good agreement between those two species.
Alternative approaches to delivering antibodies to the 
brain involve bypassing the BBB via either the intra-
nasal route or direct CNS (usually intrathecal) admin-
istration. The utility of such approaches in accessing 
particular brain areas or cell types requires knowledge 
of how antibodies move within the CNS. Pizzo et  al. 
[60] examined how IgG and smaller single-domain 
antibodies move within the rat brain after intrathecal 
administration, with a particular focus on perivascular 
transport. The perivascular route allowed the penetra-
tion of these macromolecules deep within the brain in 
contrast to diffusion across the brain surface. Interest-
ingly, they found evidence of perivascular transport 
of these molecules in all vessels, including capillaries 
(see below) and reported that perivascular flow was 
enhanced by osmolyte co-infusion with the antibodies.
Much of the in vivo evidence on small drug penetra-
tion into brain has been derived from rodent stud-
ies. There are concerns that there may be differences 
between species in drug penetration, particularly if 
there is a transporter component in either influx or 
efflux. There has, therefore, been interest in devel-
oping humanized mouse models expressing human 
transporters. Sano et  al. [81] reports development of 
such a mouse expressing the organic anion transporter 
OATP1A2 in the brain endothelial cell although, unfor-
tunately, it had little effect on the brain penetration of 
the substrates examined.
There continues to be great interest in developing 
methods to disrupt the BBB to enhance drug delivery. 
One approach is the use of focused ultrasound and 
Arvantis et al. [82] reports studies on a mouse model of 
brain metastases. Interestingly, they found that focused 
ultrasound in combination with microbubbles not only 
enhanced barrier permeability, it also increased inter-
stitial convective transport.
A proposed alternate approach for increasing drug 
delivery via enhanced neurovascular permeability is to 
use endogenous signaling pathways that regulate bar-
rier function. There is preclinical evidence that activa-
tion of the adenosine A2A receptor can cause transient 
enhanced permeability and Jackson et  al. [83] exam-
ined whether an A2A receptor agonist, regadenoson, 
could enhance temozolomide concentrations in brain 
in glioblastoma patients. The initial results indicated 
no enhancement. This again shows the difficulty of 
translating preclinical data to patients and further 
pharmacodynamic and pharmacokinetic studies are 
needed.
Fluid movement within the brain
Fluids and Barriers of the CNS is currently producing a 
thematic series on this subject, entitled, CNS Fluid and 
Solute Movement: Physiology, Modeling and Imaging.
Perivascular and parenchymal fluid flow
The concept of a glymphatic system has engendered a 
surge in interest in fluid (and associated solute) flow 
within the brain [84]. The proposed glymphatic system 
involves fluid entry into brain along the arterial perivas-
cular space, fluid movement through brain parenchyma 
that is astrocyte and aquaporin-4 dependent, and fluid 
exit from brain along the venous perivascular space. 
There is evidence that this system is altered by variables 
such as exercise [85], circadian rhythm [86] and disease 
states [84]. However, recently the concept of a glymphatic 
system has been vigorously debated (for reviews see [84, 
87]).
Most evidence for the glymphatic system comes from 
studies on perivascular flow using two-photon micros-
copy and also now with Magnetic Resonance Imaging 
[88–90]. However, it should be noted that even that com-
ponent has been questioned. For example, Faghih et  al. 
[13] have tried to computer model fluid flow within the 
glymphatic system and found it implausible based on 
current anatomical and pressure gradient data. Another 
modeling paper, Rey and Sarntinoranont [14], also pre-
dicted that fluid flow in the perivascular space would be 
oscillatory with no net flow over time. Most studies of the 
glymphatic system are currently based on solute tracking 
rather than measuring fluid flow and new techniques to 
examine the latter could be very informative.
The parenchymal component (astrocyte/aquaporin-4 
mediated) of the glymphatic system has been the most 
difficult to study. However, Huber et al. [91] did recently 
report that an aquaporin-4 facilitator promotes brain 
interstitial fluid circulation. Recently, a potential alter-
nate link between the periarterial and perivenous spaces 
has been proposed for fluid and solute flow, a pericapil-
lary space [60]. Anatomically, the vascular basement 
membrane is secreted by endothelial cells and perivas-
cular cells (pericytes/astrocytes) and a gap between these 
types of the basement membrane may form the basis of 
a pericapillary space [59]. Also in contrast to the origi-
nal glymphatic hypothesis, a recent study by Albargothy 
et al. [92] concluded that tracers in the CSF pass into the 
brain parenchyma along the pia-glial basement mem-
brane alongside arteries and exit the brain along intramu-
ral pericapillary and periarterial basement membranes.
One proposed role of the glymphatic system is in the 
clearance of potentially toxic peptides/proteins from the 
brain, including β-amyloid [84]. The evidence on the 
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relative importance of perivascular drainage of β-amyloid 
versus BBB transport has recently been reviewed in 
depth by Hladky and Barrand [44]. They contend that 
the current evidence favors the BBB as being the most 
important route.
CSF flow and drainage
CSF flow and the role of the choroid plexus continues 
to be somewhat of a contentious subject [93]. However, 
recent evidence shows the critical importance of CSF 
flow. Petrik et al. [94] found that alterations in ventricular 
fluid flow promote proliferation in subependymal zone 
neural stem cells in mice by eliciting Na and Ca signaling 
in those cells. This signaling only occurred in neural stem 
cells in contact with ventricular fluid. Thus, CSF flow has 
a central role in regulating adult neurogenesis and the 
implications of this for conditions with altered CSF flow, 
e.g. hydrocephalus, need to be explored.
The classical view that CSF drainage occurs at the 
arachnoid villi of the sagittal and transverse sinuses has 
been challenged for decades with a growing understand-
ing of the importance of drainage across the cribriform 
plate to the nasal lymphatics/cervical lymph nodes and 
drainage via the spinal nerve roots to the lumbar lymph. 
More recently, the importance of meningeal lymphat-
ics that also drain to the cervical lymph nodes has been 
highlighted. Da Mesquita et al. [95] examined the effects 
of manipulating meningeal lymphatics using a variety 
of techniques to inhibit drainage in mice and vascular 
endothelial growth factor C to enhance those lymphat-
ics. They found that meningeal lymphatic dysfunction 
aggravates age-associated cognitive decline, Alzheimer’s 
disease pathology and β-amyloid accumulation, while 
enhancing lymphatic drainage improved learning and 
memory in mice. Similarly, Louveau et  al. [96] provides 
evidence on the importance of meningeal lymphatics in 
neuroinflammation. Ma et al. recently found using fluo-
rescent tracers and imaging in awake and anesthetized 
mice, that tracers exited to the lymphatic system faster 
with slower spread into the brain perivascular spaces in 
awake mice than when anesthetized [97].
Disease states
Hydrocephalus
Congenital hydrocephalus is difficult to treat success-
fully and has a variety of causes. Fetal MRI can reveal 
anatomic features that predict aqueduct stenosis which 
can help in subsequent obstetric management [98]. There 
continues to be an interest in the role of ependymal cilia 
in the development of hydrocephalus. Abdelhamed et al. 
[99] found that a homozygous splice site mutation in 
the coiled-coil domain containing 39 (Ccdc39) protein 
causes the progressive hydrocephalus that occurs in the 
prh mouse. Those mice develop shorter ependymal cilia 
with disorganized microtubules. Similarly, mouse mod-
els lacking the ciliary proteins CFAP221, CFAP54 and 
SPEF2 all develop hydrocephalus, the severity of which 
depends on the background strain. McKenzie et al. [100] 
have examined the genetic basis of that variation, identi-
fying genes involved in brain and cilia development and 
function. Malfunctioning genes that regulate neural tube 
development and neural stem cell fate also lead to abnor-
mal neurogenesis and congenital hydrocephalus [101].
In premature infants and in adults, post-hemorrhagic 
hydrocephalus is a major clinical problem and the 
Hydrocephalus Association hosted a conference on the 
topic to discuss opportunities for research and encourage 
further research efforts. A summary of that meeting has 
been published [102]. There has long been an interest in 
whether choroid plexus ion transport might be targeted 
as a therapy for hydrocephalus. For example, in 2017 
Karimy et  al. [103] provided preclinical data that intra-
ventricular hemorrhage causes CSF hypersecretion by 
stimulating choroid plexus Na/K/Cl cotransport. In 2018, 
Li et al. [104] found that germinal matrix hemorrhage in 
neonatal rats induces upregulation of the sodium-cou-
pled bicarbonate exchanger (NCBE) and targeting that 
transporter using small interfering RNAs reduces post-
hemorrhagic hydrocephalus.
Idiopathic intracranial hypertension is a syndrome of 
unknown cause in obese patients with high intracranial 
pressure, without ventriculomegaly but with associated 
visual disturbances and morbidity. A multivariate analy-
sis showed that anemia and NSAID use were risk factors 
[105]. There is some evidence that the condition is related 
to abnormal pressure in the cranial venous sinuses affect-
ing CSF drainage [106, 107].
The pathogenesis of normal pressure hydrocepha-
lus (NPH), which occurs in the elderly, is unclear. A 
large group of possible NPH patients studied in Finland 
showed that confirmed NPH patients had a higher inci-
dence of hypertension or type-2 diabetes mellitus and 
that cardiovascular and cerebrovascular disease was the 
most frequent cause of death [108]. A cohort of Finish 
and Norwegian NPH patients was found to have a four-
fold higher incidence of copy number loss in intron 2 of 
SFMBT1 than normal although the pathogenic role was 
not clear [109]. Treatment is usually performed when 
patients show classic symptoms of gait disturbance, 
mental and urinary problems. A small study however, 
has shown that patients develop enlarged ventricles at 
least 3  years before symptoms are apparent, suggesting 
possible implications for management [110]. Diagnosis 
most often relies on invasive infusion techniques. For 
example, as part of a clinical trial, the intracranial CSF 
dynamic profile was studied by infusion in NPH patients 
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and found to differ from that of healthy controls [111]. 
Recently, an MRI study on healthy individuals by Bur-
man et  al. [112] determined the relative distribution of 
compliance between the spinal and cranial CSF compart-
ments and proposed a model that can be used to estimate 
both the cranial compliance and intracranial pressure 
non-invasively. Hence, non-invasive MRI techniques 
continue to be a promising route to aid diagnosis and 
determine shunt surgery response. Computerized volu-
metric analysis of the CSF spaces enabled good discrimi-
nation between NPH and brain atrophy patients [113] 
and the apparent diffusion coefficient of water measured 
in different brain regions can distinguish between NPH 
patients and patients with vascular dementia or Alzhei-
mer’s disease [114]. On the other hand, specific features 
of MR images in NPH patients are not good predic-
tors for reversibility of symptoms after shunt surgery 
[115]. The same group reported that around 40% show 
improved symptoms after surgery [116]. Many CSF bio-
markers continue to be investigated as a tool to predict 
treatment outcome for NPH: promising compounds sug-
gested to warrant further investigation are Aβ42, tau, 
p-tau, neurofilament light protein (NFL) and leucine-rich 
α-2-glycoprotein (LRG) [117].
Role of NVU/BBB changes in neurological conditions
NVU/BBB functions are altered in many neurological 
conditions. There have been multiple reviews in 2018 
outlining the current state of knowledge with regards to 
Alzheimer’s disease and other neurodegenerative dis-
eases [118–120], ischemic stroke [51, 121], hemorrhagic 
stroke [122], multiple sclerosis [51] and primary and met-
astatic brain cancer [51]. Importantly, these reviews serve 
to highlight that NVU/BBB changes are not just a conse-
quence of parenchymal injury, but may actually contrib-
ute to that injury and are a therapeutic target. Thus, for 
example, targeting the vascular changes in Alzheimer’s 
disease and cerebral ischemia may reduce disease pro-
gression [120, 121]. Recent results also indicate that brain 
endothelial cell dysfunction is the underlying cause of 
white matter injury in cerebral small vessel disease [123]. 
That is not to say that parenchymal cell dysfunction may 
not cause NVU/BBB dysfunction. For example, Rempe 
et  al. [124] recently showed that neuronal glutamate 
release in epilepsy causes matrix metalloproteinase-2 and 
-9 upregulation that, in turn, causes BBB disruption and 
may further impact the brain.
The mechanisms by which NVU/BBB dysfunction may 
cause parenchymal cell injury in different neurological 
conditions are under investigation. There are multiple 
neuroactive compounds present in plasma that may gain 
entry into brain and participate in injury. One extensively 
studied compound is fibrinogen that has pleiotropic roles 
in CNS inflammation [125].
Another interesting question is what severity of brain 
injury is required to cause NVU/BBB dysfunction. A 
recent porcine study suggests that concussion causes 
mechanical BBB disruption [126]. Indeed, a study on 
high school American football players indicates that even 
sub-concussive (clinically asymptomatic) high accelera-
tion hits during a season result in elevated levels of brain 
injury markers in serum [127]. The appearance of these 
brain proteins (tau and ubiquitin C-terminal hydrolase 
L1) in serum may involve some NVU/BBB disruption. 
Tagge et al. [128], studying mice also found that closed-
head injuries can cause neuropathology including micro-
vascular injury independent of signs of concussion.
Heterogeneity
Temporal heterogeneity
Far from being static entities, the blood–brain barriers 
show dynamic change with time (long- and short-term). 
While there have been many studies examining the 
development of the blood–brain and blood-CSF barriers, 
including in 2018 (e.g. [19, 129]), the impact of ageing 
on these barriers is still receiving relative little attention. 
Such changes may participate in disease susceptibil-
ity, even in people without neurodegenerative diseases. 
Goodall et  al. [130] examined the impact of ageing in 
humans and mice on BBB function. They found increased 
TJ breaks in mice with age and increased brain vascular 
permeability (protein extravasation) in humans with age. 
Similarly, Stamatovic et al. [131] found increased vascu-
lar permeability and altered TJ organization with ageing 
in mice. Interestingly, they found that these changes were 
associated with decreased brain endothelial sirtuin-1 
(Sirt-1) expression and that Sirt-1 regulates BBB func-
tion (e.g. cell-specific knockout increases permeability). 
Importantly, they also found evidence that down-regula-
tion of brain endothelial Sirt-1 also occurs in the human 
brain with ageing.
In addition to long-term temporal changes in function 
of the blood–brain barriers, there is growing evidence 
for short-term changes not only in response to injury 
but also in the normal brain. Thus, the choroid plexus 
displays a circadian rhythm, with circadian changes in 
the expression of ‘clock genes’ [132]. Importantly, those 
changes may, via the CSF, impact the suprachiasmatic 
nucleus of the hypothalamus, the location of the main 
mammalian circadian clock [132]. One impact of the 
choroid plexus circadian rhythm are changes in the clear-
ance of metabolic waste products [133]. A recent study 
on the drosophila ‘equivalent’ of the BBB also detected a 
circadian rhythm with alterations in efflux transport [20]. 
There has been considerable interest on the effects of 
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sleep on the glymphatic system and metabolic clearance 
[134]. How these barrier and fluid flow changes are inte-
grated merits further attention.
Spatial heterogeneity
As well as temporal heterogeneity, there is growing evi-
dence of spatial heterogeneity in the NVU/BBB. Thus, 
there is evidence of differences in barrier function 
between different areas of the brain that might impact 
the course of neuropathology [135]. Interestingly, Wang 
et al. recently discovered that the role of the Norrin and 
Wnt7a/Wnt7b signaling systems in NVU/BBB and blood-
retinal barrier development shows marked regional het-
erogeneity [129].
In an important study, Vanlandewijck et  al. [136] 
used single cell transcriptomics to examine changes in 
endothelial and mural cell gene expression going from 
arterial, capillary, to venous vessels (zonation). That 
study, and the associated searchable database, demon-
strates marked effects of zonation on gene expression, 
e.g. for some genes there are marked changes in expres-
sion between arterial, capillary and venous endothelial 
cells. It should be noted that at the protein level differ-
ences in expression have be found even between adjacent 
endothelial cells (e.g. [137]).
Future directions
Brain barrier and brain fluid research continues to be 
a vibrant field with many groups participating in this 
exciting area of CNS investigation. Insights from scien-
tists in other areas, such as imaging, bioengineering and 
computer modeling, are helping to advance the field. 
Research has also been inspired by discoveries in other 
tissues. As with 2018, 2019 promises to be a year of pro-
vocative and important findings and we look forward to 
further excellent contributions to Fluids Barriers of the 
CNS.
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